Latest Content

The editor in chief of Evidence-Based Oncology calls for universal biomarker testing in every patient, the same standard set for patients in his practice.

Research indicates that prior authorizations for drugs take physician practices and pharmacies 15 to 64 minutes to complete and cost $15 to $63 each.

Data confirm the use of daratumumab, bortezomib, lenalidomide, and dexamethasone as the standard of care in newly diagnosed multiple myeloma.

Children aged 2 to 5 years with fall birthdays had higher flu vaccination rates and fewer diagnoses than those with summer birthdays.

FDA approves ensitrelvir for COVID-19 post-exposure prophylaxis following phase 3 data showing efficacy against Omicron symptoms.

The combination of pharmacotherapy and psychotherapy is associated with reductions in emergency department visits and inpatient admissions along with lower total cost of care relative to either therapy alone.

Asthma and Allergy Awareness Month shines light on the ways that asthma can affect long-term health.

Phase 3 trials show bepirovirsen delivers ~20% functional cure in chronic hepatitis B in just 24 weeks.

An entirely new approach to treating one of the most intractable cancers could turn it into a chronic disease.